Literature DB >> 28917628

An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Amy Singleton1, Danika Khong1, Ling-Yee Chin1, Shilpaa Mukundan1, Matthew Li1, Biju Parekkadan2.   

Abstract

BACKGROUND AIMS: Cell transplants offer a new opportunity to deliver therapies with novel and complex mechanisms of action. Understanding the pharmacology of cell transplants is important to deliver this new therapy effectively. Currently, however, there are limited techniques to easily track cells after intravenous administration due to the dispersion of the graft throughout the entire body.
METHODS: We herein developed an engineered cell system that secretes a luciferase enzyme to sensitively detect cell transplants independent of their locale by a simple blood test. We specifically studied a unique feature of cell transplant pharmacology-namely, immune clearance-using mesenchymal stromal cells (MSCs) as a proof-of-concept cell therapy. MSCs are a clinically relevant cell therapy that has been explored in several disease indications due to their innate properties of altering an immune response.
RESULTS: Using this engineered reporter, we observed specific sensitivity of cell therapy exposure to the preparation of cells, cytolysis of MSCs in an allogeneic setting and a NK cell-mediated destruction of MSCs in an autologous setting.
CONCLUSIONS: Our cellular tracking method has broader implications at large for assessing in vivo kinetics of various other cell therapies.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MSC; NK cell; engineered MSCs; immune clearance; immunogenicity; luciferase

Mesh:

Substances:

Year:  2017        PMID: 28917628      PMCID: PMC5723229          DOI: 10.1016/j.jcyt.2017.08.003

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  45 in total

1.  Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells.

Authors:  Jakub Tolar; Matthew J O'shaughnessy; Angela Panoskaltsis-Mortari; Ron T McElmurry; Scott Bell; Megan Riddle; R Scott McIvor; Stephen R Yant; Mark A Kay; Diane Krause; Catherine M Verfaillie; Bruce R Blazar
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

Review 2.  Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.

Authors:  Donald G Phinney; Darwin J Prockop
Journal:  Stem Cells       Date:  2007-09-27       Impact factor: 6.277

3.  A secreted luciferase for ex vivo monitoring of in vivo processes.

Authors:  Thomas Wurdinger; Christian Badr; Lisa Pike; Ruben de Kleine; Ralph Weissleder; Xandra O Breakefield; Bakhos A Tannous
Journal:  Nat Methods       Date:  2008-01-20       Impact factor: 28.547

4.  Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells.

Authors:  Lior Zangi; Raanan Margalit; Shlomit Reich-Zeliger; Esther Bachar-Lustig; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

Review 5.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

6.  Immunogenicity of induced pluripotent stem cells.

Authors:  Tongbiao Zhao; Zhen-Ning Zhang; Zhili Rong; Yang Xu
Journal:  Nature       Date:  2011-05-13       Impact factor: 49.962

7.  Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.

Authors:  L F Porrata; D J Inwards; M Q Lacy; S N Markovic
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

8.  Imaging of luciferase secretion from transformed Chinese hamster ovary cells.

Authors:  S Inouye; Y Ohmiya; Y Toya; F I Tsuji
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

9.  Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production.

Authors:  Edilberto Postól; André Meyer; Fabíola Cardillo; Raquel de Alencar; Daniel Pessina; Jorge Nihei; Mário Mariano; José Mengel
Journal:  Immunology       Date:  2008-04-07       Impact factor: 7.397

10.  Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells.

Authors:  Jessica S Elman; Ryan C Murray; Ryan M Murray; Fangjing Wang; Keyue Shen; Shan Gao; Kevin E Conway; Martin L Yarmush; Bakhos A Tannous; Ralph Weissleder; Biju Parekkadan
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more
  2 in total

1.  Turning stem cells homing potential into cancer specific drug delivery machines.

Authors:  Nedime Serakinci; Huseyin Cagsin
Journal:  Ann Transl Med       Date:  2019-07

2.  Ex vivo perfusion-based engraftment of genetically engineered cell sensors into transplantable organs.

Authors:  Ling-Yee Chin; Cailah Carroll; Siavash Raigani; Danielle M Detelich; Shannon N Tessier; Gregory R Wojtkiewicz; Stephen P Schmidt; Ralph Weissleder; Heidi Yeh; Korkut Uygun; Biju Parekkadan
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.